+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 60Years
All Genders
ID07139743

Safety and Early Effectiveness Study of Obe-cel in Adults with Refractory Progressive Multiple Sclerosis

Led by Autolus Limited · Updated on 2026-10-16

24

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and early signs of effectiveness of obe-cel in adults with refractory progressive multiple sclerosis MS who have not responded to at least two disease-modifying therapies. This Phase 1 study focuses on participants with progressive forms of MS to assess whether obe-cel causes any side effects and to gather preliminary data on its potential benefits. Participants will first undergo chemotherapy over one to three days to prepare their body for treatment by reducing certain immune cells. After this lymphodepletion, they will receive a single infusion of obe-cel. The study includes a screening period, a treatment period beginning at enrollment with lymphodepletion and the infusion on Day 1, followed by a post-treatment period for ongoing monitoring. Throughout the study, participants will be closely observed for safety during the 28 days following the infusion and continue to be monitored for up to 24 months. Researchers will assess safety outcomes including dose-limiting toxicities and overall tolerability, as well as preliminary efficacy using measures such as the Expanded Disability Status Scale, Timed 25-foot Walk Test, 9-hole Peg Test, and Symbol Digit Modalities Test to evaluate changes in disability and function.

CONDITIONS

Brief Title

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Research Team

A

Autolus Ltd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here